TW202220666A - 含有賽佩普斯特(sepetaprost)之醫藥製劑 - Google Patents
含有賽佩普斯特(sepetaprost)之醫藥製劑 Download PDFInfo
- Publication number
- TW202220666A TW202220666A TW110129745A TW110129745A TW202220666A TW 202220666 A TW202220666 A TW 202220666A TW 110129745 A TW110129745 A TW 110129745A TW 110129745 A TW110129745 A TW 110129745A TW 202220666 A TW202220666 A TW 202220666A
- Authority
- TW
- Taiwan
- Prior art keywords
- glaucoma
- ocular hypertension
- treatment
- mentioned
- pharmaceutical preparation
- Prior art date
Links
- BKVUSNOUTQMSBE-XCMGCKIWSA-N propan-2-yl 4-[(3s,5ar,6r,7r,8as)-6-[(e,3r)-4-(2,5-difluorophenoxy)-3-hydroxybut-1-enyl]-7-hydroxy-3,4,5,5a,6,7,8,8a-octahydro-2h-cyclopenta[b]oxepin-3-yl]butanoate Chemical compound C([C@H](O)/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1CC[C@@H](CO2)CCCC(=O)OC(C)C)OC1=CC(F)=CC=C1F BKVUSNOUTQMSBE-XCMGCKIWSA-N 0.000 title abstract description 4
- 239000013583 drug formulation Substances 0.000 title abstract 5
- 229950000863 sepetaprost Drugs 0.000 title abstract 3
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 187
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 170
- 239000004480 active ingredient Substances 0.000 claims abstract description 88
- 230000000694 effects Effects 0.000 claims abstract description 52
- 230000002265 prevention Effects 0.000 claims abstract description 41
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 89
- 230000004410 intraocular pressure Effects 0.000 claims description 86
- 239000003814 drug Substances 0.000 claims description 72
- 229940079593 drug Drugs 0.000 claims description 60
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 54
- 229960001160 latanoprost Drugs 0.000 claims description 51
- 239000003889 eye drop Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 42
- 230000003449 preventive effect Effects 0.000 claims description 12
- 229940126585 therapeutic drug Drugs 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 claims description 5
- 230000001568 sexual effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims 1
- 230000009471 action Effects 0.000 abstract description 2
- 229940012356 eye drops Drugs 0.000 description 31
- 241000282693 Cercopithecidae Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 13
- 210000001508 eye Anatomy 0.000 description 12
- 239000000556 agonist Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 10
- 239000000018 receptor agonist Substances 0.000 description 8
- 229940044601 receptor agonist Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000006196 drop Substances 0.000 description 7
- 230000001077 hypotensive effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 230000002889 sympathetic effect Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 239000002876 beta blocker Substances 0.000 description 6
- -1 niprol Chemical compound 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 230000001734 parasympathetic effect Effects 0.000 description 6
- 230000004043 responsiveness Effects 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 5
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003590 rho kinase inhibitor Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 3
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 3
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 3
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 3
- 229960000571 acetazolamide Drugs 0.000 description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229960004324 betaxolol Drugs 0.000 description 3
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 3
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 3
- 229960002470 bimatoprost Drugs 0.000 description 3
- 229960003679 brimonidine Drugs 0.000 description 3
- 229960001222 carteolol Drugs 0.000 description 3
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 3
- 229960000831 levobunolol Drugs 0.000 description 3
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960001416 pilocarpine Drugs 0.000 description 3
- 201000006366 primary open angle glaucoma Diseases 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 229960004605 timolol Drugs 0.000 description 3
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 3
- 229960002368 travoprost Drugs 0.000 description 3
- 229950008081 unoprostone isopropyl Drugs 0.000 description 3
- VGMVBPQOACUDRU-UHFFFAOYSA-N 5-amino-1,3,4-thiadiazole-2-sulfonamide Chemical compound NC1=NN=C(S(N)(=O)=O)S1 VGMVBPQOACUDRU-UHFFFAOYSA-N 0.000 description 2
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 2
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010067013 Normal tension glaucoma Diseases 0.000 description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 229960002467 bunazosin Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 201000002978 low tension glaucoma Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 201000004616 primary angle-closure glaucoma Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229940002639 xalatan Drugs 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 206010074026 Exfoliation glaucoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000004147 hypersecretion glaucoma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229960002704 metipranolol Drugs 0.000 description 1
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
- 230000004493 normal intraocular pressure Effects 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020136796 | 2020-08-13 | ||
| JP2020-136796 | 2020-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202220666A true TW202220666A (zh) | 2022-06-01 |
Family
ID=80248014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110129745A TW202220666A (zh) | 2020-08-13 | 2021-08-12 | 含有賽佩普斯特(sepetaprost)之醫藥製劑 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230285411A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4197540A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022034909A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230051199A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115768433A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202220666A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022034909A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202404569A (zh) | 2022-04-22 | 2024-02-01 | 日商參天製藥股份有限公司 | 含有賽佩普斯特(Sepetaprost)之眼科用組合物 |
| TW202517277A (zh) * | 2023-10-10 | 2025-05-01 | 日商參天製藥股份有限公司 | 含有賽佩普斯特(Sepetaprost)之點眼液 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011013651A (ja) | 2009-07-03 | 2011-01-20 | Mitsumasa Maeda | フレキシブルディスプレイのれん |
| KR101768235B1 (ko) | 2009-07-28 | 2017-08-14 | 오노 야꾸힝 고교 가부시키가이샤 | 이환식 화합물 및 이의 의약 용도 |
| WO2019124489A1 (ja) * | 2017-12-21 | 2019-06-27 | 参天製薬株式会社 | セペタプロストとep2アゴニストとの組み合わせ医薬 |
| EP3730138B1 (en) * | 2017-12-21 | 2024-02-14 | Santen Pharmaceutical Co., Ltd. | Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension |
| US11666563B2 (en) * | 2017-12-28 | 2023-06-06 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
| JP2022508715A (ja) * | 2018-10-15 | 2022-01-19 | オキュフィア・ファーマ・インコーポレイテッド | 緑内障および関連状態の処置のための方法および組成物 |
-
2021
- 2021-08-12 JP JP2022542874A patent/JPWO2022034909A1/ja active Pending
- 2021-08-12 EP EP21855988.8A patent/EP4197540A4/en active Pending
- 2021-08-12 US US18/040,894 patent/US20230285411A1/en active Pending
- 2021-08-12 TW TW110129745A patent/TW202220666A/zh unknown
- 2021-08-12 KR KR1020237006743A patent/KR20230051199A/ko active Pending
- 2021-08-12 WO PCT/JP2021/029701 patent/WO2022034909A1/ja not_active Ceased
- 2021-08-12 CN CN202180044806.9A patent/CN115768433A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022034909A1 (cg-RX-API-DMAC7.html) | 2022-02-17 |
| EP4197540A4 (en) | 2024-06-19 |
| KR20230051199A (ko) | 2023-04-17 |
| US20230285411A1 (en) | 2023-09-14 |
| WO2022034909A1 (ja) | 2022-02-17 |
| CN115768433A (zh) | 2023-03-07 |
| EP4197540A1 (en) | 2023-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6383058B2 (ja) | スルホンアミド化合物の組み合わせ | |
| EP2671586B1 (en) | Drug therapy for preventing or treating glaucoma | |
| US20220387372A1 (en) | Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor | |
| US20140018350A1 (en) | Combination of sulfonamide compound and tafluprost | |
| JP7346305B2 (ja) | ピリジルアミノ酢酸化合物を含有する医薬製剤 | |
| CN115768433A (zh) | 含有司培前列素的医药制剂 | |
| JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| JPWO2005079792A1 (ja) | 重症糖尿病網膜症の予防又は治療剤 | |
| HK40102807B (en) | Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension | |
| HK40102807A (en) | Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension | |
| JP2023110029A (ja) | オミデネパグの組合せ | |
| HUT65880A (en) | Process for preparation of ophtalmological medicaments containing pyridine derivatives usefules for treatment of ocular hypertension | |
| EA043474B1 (ru) | Комбинация омиденепага | |
| EA050493B1 (ru) | ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ КОМБИНАЦИЮ СЕПЕТАПРОСТА И ИНГИБИТОРА Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ | |
| HK40029829B (en) | Combination of sepetaprost and ripasudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension | |
| HK1236848B (en) | Pharmacotherapy for preventing or treating glaucoma | |
| HK40031074A (en) | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | |
| US20040006142A1 (en) | Ocular tension depressor |